CA2128591A1 - Controlled Release Formulations Coated with Aqueous Dispersions of Acrylic Polymers - Google Patents

Controlled Release Formulations Coated with Aqueous Dispersions of Acrylic Polymers

Info

Publication number
CA2128591A1
CA2128591A1 CA 2128591 CA2128591A CA2128591A1 CA 2128591 A1 CA2128591 A1 CA 2128591A1 CA 2128591 CA2128591 CA 2128591 CA 2128591 A CA2128591 A CA 2128591A CA 2128591 A1 CA2128591 A1 CA 2128591A1
Authority
CA
Canada
Prior art keywords
agent
controlled release
release formulations
acrylic polymers
aqueous dispersions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2128591
Other languages
French (fr)
Other versions
CA2128591C (en
Inventor
Benjamin Oshlack
Mark Chasin
Frank Pedi, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euroceltique SA
Original Assignee
Benjamin Oshlack
Mark Chasin
Frank Pedi, Jr.
Euroceltique, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/097,558 priority Critical patent/US5580578A/en
Priority to US097,558 priority
Application filed by Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr., Euroceltique, S.A. filed Critical Benjamin Oshlack
Publication of CA2128591A1 publication Critical patent/CA2128591A1/en
Application granted granted Critical
Publication of CA2128591C publication Critical patent/CA2128591C/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, overcoated with an aqueous dispersion of the plasticized water-insoluble acrylic polymer.
The formulation provides a stable dissolution of the active agent which is unchanged after exposure to accelerated storage conditions.
CA 2128591 1992-01-27 1994-07-21 Controlled release formulations coated with aqueous dispersions of acrylic polymers Expired - Lifetime CA2128591C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/097,558 US5580578A (en) 1992-01-27 1993-07-27 Controlled release formulations coated with aqueous dispersions of acrylic polymers
US097,558 1993-07-27

Publications (2)

Publication Number Publication Date
CA2128591A1 true CA2128591A1 (en) 1995-01-28
CA2128591C CA2128591C (en) 1999-03-23

Family

ID=22264016

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2128591 Expired - Lifetime CA2128591C (en) 1992-01-27 1994-07-21 Controlled release formulations coated with aqueous dispersions of acrylic polymers

Country Status (4)

Country Link
US (3) US5580578A (en)
EP (1) EP0636366A3 (en)
AU (1) AU686168B2 (en)
CA (1) CA2128591C (en)

Families Citing this family (919)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
HU218673B (en) * 1993-10-07 2000-10-28 Euroceltique S.A. Controlled release pharmaceutical composition for orally administration comprising opioid analgesic and process for producing its
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
SK177598A3 (en) * 1996-06-28 1999-07-12 Schering Corp Oral composition comprising a triazole antifungal compound
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
DE69739181D1 (en) * 1996-08-12 2009-02-05 Celgene Corp New immunotherapeutic agents and their use in reducing Cytokinenspiegel
US5776856A (en) * 1997-02-04 1998-07-07 Isp Investments Inc. Soluble polymer based matrix for chemically active water insoluble components
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
WO1999001111A1 (en) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
IN186245B (en) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd Process for the preparation of a pharmaceutical composition in the form of oral controlled release tablets or capsules
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
DK1041987T3 (en) 1997-12-22 2006-08-21 Euro Celtique Sa An oral pharmaceutical dosage form comprising a combination of an opioid agonist and naltrexone
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
FR2774910B1 (en) * 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques morphine sulfate microgranules, method for making and pharmaceutical preparations
US6471975B1 (en) 1998-05-01 2002-10-29 3M Innovative Properties Company Microspheres as a delivery vehicle for bio-active agents useful in agricultural applications
US7354596B1 (en) 1998-05-01 2008-04-08 3M Innovative Properties Company Anti-microbial agent delivery system
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
TR200103762T2 (en) 1998-06-15 2002-05-21 Sepracor Inc. Apnea, bulimia and optically pure for the treatment of other disorders (-) norcisapride use.
KR20060017570A (en) * 1998-06-15 2006-02-23 세프라코 아이엔시. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
DE19831869A1 (en) * 1998-07-16 2000-01-20 Merck Patent Gmbh Use of pigments based on lamellar substrate for coloring food and pharmaceutical products
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
AT411011T (en) 1998-11-02 2008-10-15 Elan Pharma Int Ltd Multiparticulate composition of methylphenidate with modified release
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6800329B2 (en) * 1999-02-12 2004-10-05 Lts Lohmann Therapie-Systeme Ag Method for producing film-type dosage
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CA2371822A1 (en) * 1999-03-01 2000-09-08 Timothy J. Barberich Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
AU782092B2 (en) * 1999-04-06 2005-06-30 Wyeth Llc Derivatives of venlafaxine and methods of preparing and using the same
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
FR2794646B1 (en) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques morphine sulfate microgranules process for the preparation and composition containing them
IN191239B (en) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd A process for the preparation of a taste masked composition
US7718705B1 (en) 1999-09-03 2010-05-18 Eli Lilly And Company Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1230349B1 (en) 1999-11-18 2007-06-13 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
IL151057D0 (en) 2000-02-08 2003-04-10 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
NZ521937A (en) * 2000-03-31 2004-08-27 Celgene Corp Inhibition of cyclooxygenase-2 activity
SE0001151D0 (en) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled release composition
GB2361928A (en) * 2000-05-03 2001-11-07 Procter & Gamble Elastic packaging or binder material
US6368628B1 (en) 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6338857B1 (en) 2000-05-26 2002-01-15 Pharma Pass Llc Sustained release carbamazepine pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US6663686B1 (en) 2000-06-27 2003-12-16 Agrium, Inc. Controlled release fertilizer and method for production thereof
US6858634B2 (en) * 2000-09-15 2005-02-22 Monsanto Technology Llc Controlled release formulations and methods for their production and use
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
KR100960200B1 (en) * 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
ES2220789T3 (en) * 2000-10-30 2004-12-16 Lupin Limited Composition of cefuroxime axetil slow release disintegrates quickly.
CA2428800C (en) * 2000-11-20 2011-09-13 Dow Global Technologies Inc. In vivo use of fluid absorbent polymers
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
JP4242651B2 (en) * 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション 4-Amino - Synthesis of thalidomide enantiomers
US20030167524A1 (en) * 2000-12-19 2003-09-04 Rooijen Gijs Van Methods for the production of multimeric protein complexes, and related compositions
US20040112838A1 (en) * 2001-02-09 2004-06-17 United States Filter Corporation System and method for optimized control of multiple oxidizers
WO2002064543A2 (en) * 2001-02-12 2002-08-22 Wyeth Novel succinate salt of o-desmethyl-venlafaxine
US20040172169A1 (en) * 2001-03-02 2004-09-02 Curtis Wright Method and apparatus for compouding individualized dosege forms
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US20030143272A1 (en) * 2001-03-14 2003-07-31 Waterman Kenneth C. Pharmaceutical tablet and process for making thereof
EP1383884A4 (en) 2001-03-22 2004-12-15 Dendreon Corp Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
AU2002303614B2 (en) 2001-05-02 2005-02-10 Euro-Celtique S.A. Once-a-day oxycodone formulations
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
KR20040080940A (en) 2001-05-14 2004-09-20 덴드레온 코포레이션 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US6623785B2 (en) * 2001-06-07 2003-09-23 Hewlett-Packard Development Company, L.P. Pharmaceutical dispensing apparatus and method
CN100356907C (en) * 2001-06-08 2007-12-26 恩德制药公司 Controlled release dosage forms using acrylic polymer, and process for making
US20040247696A1 (en) * 2001-07-05 2004-12-09 Antelman Marvin S. Methods of using electron active compounds for managing conditions afflicting mammals
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
PL208484B1 (en) * 2001-07-06 2011-05-31 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone related applications
EP1406630A1 (en) * 2001-07-06 2004-04-14 Endo Pharmaceuticals Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
BR0211067A (en) * 2001-07-09 2006-10-31 Zonagen Inc methods and materials for the treatment of testosterone deficiency in men
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1414451B1 (en) 2001-08-06 2009-05-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US6776926B2 (en) * 2001-08-09 2004-08-17 United States Filter Corporation Calcium hypochlorite of reduced reactivity
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
JP2005523876A (en) * 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー Opioid formulations potential for abuse is reduced
US6786223B2 (en) * 2001-10-11 2004-09-07 S. C. Johnson & Son, Inc. Hard surface cleaners which provide improved fragrance retention properties to hard surfaces
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
CA2464528A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
WO2003044179A2 (en) * 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
AU2002348131A1 (en) 2001-12-05 2003-06-23 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
EP1472225B1 (en) 2002-02-01 2010-04-28 Euro-Celtique S.A. 2-piperazine-pyridines useful for treating pain
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) * 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
AT536173T (en) * 2002-02-21 2011-12-15 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US6991735B2 (en) * 2002-02-26 2006-01-31 Usfilter Corporation Free radical generator and method
US7108781B2 (en) * 2002-02-26 2006-09-19 Usfilter Corporation Enhanced air and water purification using continuous breakpoint halogenation with free oxygen radicals
AT550022T (en) 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmaceutical mixed crystals of celecoxib -nicotinamide
IL163846D0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
ES2327034T3 (en) * 2002-03-26 2009-10-23 Euro-Celtique S.A. Gel compositions coated with sustained release.
CN100411611C (en) 2002-04-05 2008-08-20 欧洲凯尔蒂克公司 Matrix for sustained, invariant and independent release of active compounds
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
MXPA04011310A (en) 2002-05-17 2005-02-14 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases.
CN103494817A (en) 2002-05-17 2014-01-08 细胞基因公司 Methods and compoistions used for treatment and control of multiple myeloma
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
JP2005535602A (en) * 2002-05-31 2005-11-24 トランスフォーム・ファーマシューティカルズ・インコーポレイテッドTransform Pharmaceuticals, Inc. New conazole crystalline forms and related methods, pharmaceutical compositions and methods
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
EP2527315B1 (en) * 2002-05-31 2014-03-19 Proteotech Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
IL165383D0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
AT376854T (en) * 2002-06-26 2007-11-15 Alza Corp Minimally compliant volume-efficient piston for osmotic drug delivery systems
WO2004004453A2 (en) * 2002-07-03 2004-01-15 Centro Internacional De Mejoramiento De Maiz Y Trigo A slow-release agrochemicals dispenser and method of use
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP1542667B1 (en) 2002-07-24 2012-03-07 PTC Therapeutics, Inc. Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20040016276A1 (en) * 2002-07-26 2004-01-29 Wynnyk Nick P. Controlled release fertilizer having improved mechanical handling durability and method for production thereof
PT1542658E (en) 2002-08-15 2011-02-03 Euro Celtique Sa Pharmaceutical compositions comprising an opioid analgesic
PL375411A1 (en) * 2002-09-03 2005-11-28 Biovail Laboratories, Inc. Pharmaceuticals formulations and methods for modified release of statin drugs
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
EP2422775A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
WO2004026262A2 (en) * 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
DE60313478T2 (en) 2002-09-25 2008-01-03 Euro-Celtique S.A. N-substituted hydromorphone and its application
WO2004028463A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of lupus using clofarabine
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20040260076A1 (en) * 2002-10-11 2004-12-23 Castillo Gerardo M. Isolation, purification and synthesis of procyanidin B2 and uses thereof
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
CA2501936A1 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US6786591B2 (en) 2002-10-24 2004-09-07 Hewlett-Packard Development Company, L.P. Fluid ejector apparatus and methods
US20040081689A1 (en) * 2002-10-24 2004-04-29 Dunfield John Stephen Pharmaceutical dosage form and method of making
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
KR100923173B1 (en) 2002-11-06 2009-10-22 셀진 코포레이션 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
WO2004043336A2 (en) * 2002-11-06 2004-05-27 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
BR0316259A (en) * 2002-11-18 2005-10-04 Celgene Corp Methods of inhibiting the production of TNF-alpha and PDE4 activity, to treat or prevent a disease or disorder, controlling cAMP levels in a cell and producing a compound, pharmaceutical composition and compound
US20040167199A1 (en) * 2002-11-18 2004-08-26 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
EP2218779A1 (en) 2002-12-16 2010-08-18 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
CN1777426A (en) 2003-03-31 2006-05-24 泰坦医药品公司 Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
SI3103800T1 (en) 2003-04-11 2018-10-30 Pct Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CA2525969A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
JP2007502329A (en) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッドTransform Pharmaceuticals, Inc. Sertraline composition
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
US7250475B2 (en) 2003-06-26 2007-07-31 Symyx Technologies, Inc. Synthesis of photoresist polymers
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
WO2005007641A1 (en) * 2003-07-03 2005-01-27 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
WO2005004882A1 (en) * 2003-07-09 2005-01-20 Monash University Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
CN101947218A (en) 2003-07-23 2011-01-19 幸讬制药公司 Method for modulating calcium ion-release-activated calcium ion channels
EP1867644B1 (en) 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
AU2004259358B2 (en) 2003-07-24 2008-03-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
BRPI0412808A (en) * 2003-07-24 2006-09-26 Euro Celtique Sa piperidine compounds and pharmaceutical compositions containing them
WO2005012287A1 (en) * 2003-08-01 2005-02-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
MXPA06002443A (en) * 2003-09-03 2006-08-31 Agi Therapeutics Ltd Proton pump inhibitor formulations, and methods of preparing and using such formulations.
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
MX342025B (en) 2003-09-04 2016-09-12 Celgene Corp * Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)- piperidine-2,6-dione.
EP1667645A1 (en) * 2003-09-19 2006-06-14 Symyx Technologies Materials for enhanced delivery of hydrophilic active agents in personal care formulations
CA2537004A1 (en) * 2003-09-22 2005-04-07 Euro-Celtique S.A. Therapeutic agents useful for treating pain
DE602004014791D1 (en) 2003-09-22 2008-08-14 Euro Celtique Sa For treatment of pain appropriate phenylcarbonsäureamidverbindungen
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
CN1901911A (en) * 2003-11-06 2007-01-24 细胞基因公司 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1692128A1 (en) 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Indazole compounds and methods of use thereof as protein kinase inhibitors
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8883204B2 (en) * 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
WO2005066130A1 (en) * 2003-12-30 2005-07-21 Euro-Celtique S.A. Piperazines useful for treating pain
WO2005067980A2 (en) * 2004-01-12 2005-07-28 Pointilliste, Inc. Design of therapeutics and therapeutics
DE102004005095A1 (en) * 2004-01-27 2005-09-22 Coty B.V. Cosmetic composition useful in sun care products, antiperspirants comprises fragrance and fragrance fixing complexes comprising hydrophobic, alcohol soluble, carboxylated acrylates/octylacrylamide copolymer and hydrolyzed jojoba ester
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
WO2005077331A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
AT397924T (en) 2004-02-18 2008-07-15 Gpc Biotech Ag Satraplatin for the treatment of resistant tumors or refrkatären
WO2005091991A2 (en) 2004-03-22 2005-10-06 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20060004037A1 (en) * 2004-03-25 2006-01-05 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
MXPA06011765A (en) * 2004-04-12 2006-12-15 Pfizer Prod Inc Taste-masked drugs in rupturing multiparticulates.
JP2007532642A (en) * 2004-04-14 2007-11-15 セルジーン・コーポレーションCelgene Corporation Using a selective cytokine inhibitory drug for the treatment and management of myelodysplastic syndromes, and compositions containing the same
US20080199422A1 (en) * 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
JP2007533697A (en) * 2004-04-22 2007-11-22 デュオコート エービーDuocort Ab Glucocorticoid pharmaceutical composition for the acute care
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
JP2007533760A (en) * 2004-04-23 2007-11-22 セルジーン・コーポレーションCelgene Corporation For managing and treating pulmonary hypertension, a composition comprising methods and pde4 modulators use pde4 modulator
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
EP1745073A2 (en) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP1755388B1 (en) 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc Addiction-prevention drug formulations
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
JP5017103B2 (en) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド Using that drug co-crystal compositions and related
US20080242726A1 (en) * 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
DE102004035938A1 (en) * 2004-07-23 2006-02-16 Röhm GmbH & Co. KG A process for preparing coated dosage forms with a stable active ingredient release profile
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
JP2008509154A (en) * 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド Novel statin pharmaceutical compositions and related methods of treatment
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
CA2578540A1 (en) * 2004-09-01 2006-03-16 Euro-Celtique S.A. Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax
CN102379872A (en) 2004-09-17 2012-03-21 弗尔德里克斯制药股份有限公司 Compounds, compositions and methods of inhibiting a-synuclein toxicity
US7709518B2 (en) 2004-09-21 2010-05-04 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
BRPI0518062A (en) * 2004-10-28 2008-10-28 Celgene Corp Use of a PDE4 modulator, or a salt, solvate, or pharmaceutically acceptable estereoisÈmero thereof, and pharmaceutical composition
US20080160099A1 (en) * 2004-11-10 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods For Treating or Preventing a Vascular Disease
EP2295416B1 (en) 2004-11-18 2016-01-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
KR20070087643A (en) * 2004-12-09 2007-08-28 셀진 코포레이션 Treatment using d-threo methylphenidate
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
JP5303149B2 (en) 2004-12-17 2013-10-02 アナディス ファーマシューティカルズ インク 3,5-disubstituted and 3,5,7-trisubstituted -3H- oxazolo and 3H- thiazolo [4,5-d] pyrimidin-2-one compounds and prodrugs thereof
US7390399B2 (en) * 2004-12-21 2008-06-24 Siemens Water Technologies Holding Corp. Water treatment control systems and methods of use
ES2327840T3 (en) 2004-12-23 2009-11-04 Gpc Biotech Ag Squaric acid derivatives with antiproliferative activity.
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
KR101158711B1 (en) * 2005-01-04 2012-06-22 테이코쿠 팔마 유에스에이, 인코포레이티드 Cooling topical patch preparation
KR20140018997A (en) * 2005-01-07 2014-02-13 신타 파마슈티칼스 코프. Compounds for inflammation and immune-related uses
NZ590359A (en) 2005-01-25 2012-08-31 Synta Pharmaceuticals Corp Pyrazine compounds for inflammation and immune-related uses
FR2881350B1 (en) * 2005-02-02 2007-04-06 Merck Generiques Soc En Comman Further oral dosage form of tianeptine
US20060169646A1 (en) * 2005-02-03 2006-08-03 Usfilter Corporation Method and system for treating water
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101115477A (en) * 2005-02-04 2008-01-30 雷普罗斯治疗公司 Methods and materials with trans-clomiphene for the treatment of male infertility
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2006102232A2 (en) * 2005-03-22 2006-09-28 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
EP1877461B1 (en) * 2005-03-24 2009-05-06 Medtronic, Inc. Modification of thermoplastic polymers
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
AT534652T (en) 2005-04-01 2011-12-15 Univ California Phosphono-pent-2-en-1-yl-nucleoside analogues and
CA2602268A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
AU2006242154B2 (en) 2005-05-02 2011-11-03 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20090111818A1 (en) * 2005-07-06 2009-04-30 Sepracor Inc. Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
DE102005032806A1 (en) * 2005-07-12 2007-01-18 Röhm Gmbh Use of a partially neutralized anionic (meth) acrylate copolymer as a coating for the manufacture of a dosage form with an active ingredient release at reduced pH values
AU2006272922A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
AU2006285144A1 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US7829120B2 (en) 2005-09-09 2010-11-09 Labopharm Inc. Trazodone composition for once a day administration
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US7905245B2 (en) * 2005-09-30 2011-03-15 Siemens Water Technologies Corp. Dosing control system and method
EP1940377A4 (en) * 2005-10-24 2010-12-08 Teikoku Pharma Usa Inc Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20070104788A1 (en) 2005-11-10 2007-05-10 Seamus Mulligan Once-daily administration of central nervous system drugs
KR20080082629A (en) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 Hepatocyte growth factor intron fusion proteins
WO2007057229A1 (en) 2005-11-21 2007-05-24 Purdue Pharma L.P. 4-oxadiazolyl-piperidine compounds and use thereof
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CA2634974A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for improved cardiac function
TW200806292A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Vinyl-phenyl derivatives for inflammation and immune-related uses
CA2639927A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
EP1983980A4 (en) * 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp Thiazole and thiadiazole compounds for inflammation and immune-related uses
EP1984338B8 (en) 2006-01-31 2013-05-22 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
JP2009526096A (en) * 2006-02-07 2009-07-16 エフ エム シー コーポレーションFmc Corporation Coating method for making a sustained-release coating
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
MX2008011633A (en) * 2006-03-13 2008-12-16 Activx Biosciences Inc Aminoquinolones as gsk-3 inhibitors.
RU2008136317A (en) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Methods and compositions for the treatment of heart failure diagnostics
KR20080102200A (en) * 2006-03-13 2008-11-24 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Formulations of sitaxsentan sodium
ES2396039T3 (en) 2006-03-16 2013-02-18 Tris Pharma, Inc. Modified release formulations containing complexes of drug-ion exchange resin
AU2007245129A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
US20070243245A1 (en) * 2006-04-17 2007-10-18 Actavis Group Ptc Hf Oral Dosage Formulations, Methods of Preparing the Same, and Methods of Reducing Food Effects on Drug Release
US20070243252A1 (en) * 2006-04-17 2007-10-18 Actavis Group Ptc Hf Oral Dosage Formulations and Methods of Preparing the Same
JP5143131B2 (en) 2006-05-30 2013-02-13 インターシア セラピューティクス,インコーポレイティド Two pieces constituting the osmotic pumping out system internal channel of the flow modulator
WO2007146671A2 (en) 2006-06-06 2007-12-21 Fluid Lines Ultaviolet light activated oxidation process for the reduction of organic carbon in semiconductor process water
WO2007145834A2 (en) * 2006-06-08 2007-12-21 Amgen Inc. Benzamide derivatives and uses related thereto
TW200808695A (en) * 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
CA2655205A1 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
BRPI0713680A2 (en) 2006-06-22 2012-10-23 Anadys Pharmaceuticals Inc compound, pharmaceutical composition and methods of modulating immune cytokine activities, virus infection treatment of hepatitis C in a patient, proliferation related disorder treatment in the same lacked mammal
CN102584649A (en) 2006-06-22 2012-07-18 安那迪斯药品股份有限公司 Pyrro[1,2-b]pyridazinone compounds
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
EP2037888A2 (en) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
AT530644T (en) * 2006-07-05 2011-11-15 Catalyst Biosciences Inc Protease screening procedure, and thereby identified proteases
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
JP5225991B2 (en) 2006-07-18 2013-07-03 アナディス ファーマシューティカルズ インク Thiazolo [4,5-d] carbonate pyrimidine and carbamate prodrugs
CL2007002218A1 (en) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine 2,6-dione for the preparation of a medicament useful for the treatment of lymphoma cell layer medicine.
US20080045603A1 (en) * 2006-08-04 2008-02-21 John Devane Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ES2426350T3 (en) 2006-08-30 2013-10-22 Celgene Corporation Isoindoline compounds substituted 5
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
ZA200902091B (en) 2006-09-21 2010-07-28 Activx Biosciences Inc Serine hydrolase inhibitors
RS52349B (en) 2006-09-26 2012-12-31 Celgene Corporation 5-substituted quinazolinone derivatives as antitumor agents
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
JP2010522135A (en) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ,インコーポレイテッド Pharmaceutical compositions
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
AU2007310949A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
JP5550906B2 (en) 2006-10-19 2014-07-16 ゲンズイメ コーポレーション Purine derivatives for the treatment of cystic disease
US8733274B2 (en) * 2006-10-20 2014-05-27 Hewlett-Packard Development Company, L.P. Tube mounted inkjet printhead die
US7867548B2 (en) * 2006-10-27 2011-01-11 Hewlett-Packard Development Company, L.P. Thermal ejection of solution having solute onto device medium
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008063504A2 (en) 2006-11-13 2008-05-29 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
WO2008066789A2 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
EP2091519B1 (en) * 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
CA2671426C (en) 2006-12-13 2015-05-26 Temple University - Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues useful in the treatment of cancer and other proliferative disorders
MX2009006812A (en) * 2006-12-22 2009-07-02 Encysive Pharmaceuticals Inc Modulators of c3a receptor and methods of use thereof.
EP2121580A2 (en) * 2006-12-26 2009-11-25 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
RS51474B (en) 2007-01-16 2011-04-30 Purdue Pharma L.P. Heterocyclic-substituted piperidines as orl-1 ligands
CN101610995B (en) 2007-02-09 2017-08-08 症变治疗公司 Glucagon receptor antagonists
RU2477269C2 (en) 2007-02-21 2013-03-10 Суновион Фармасьютикалз Инк. Solid forms containing (-)-o-desmethylvenlafaxine and use thereof
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
JP2010520200A (en) * 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ,インコーポレイテッド Method of treating liver disease using certain matrix metalloproteinase (mmp) inhibitors
AU2008223091B2 (en) * 2007-03-02 2014-04-24 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US7879747B2 (en) * 2007-03-30 2011-02-01 Kimberly-Clark Worldwide, Inc. Elastic laminates having fragrance releasing properties and methods of making the same
US9365436B2 (en) 2007-04-03 2016-06-14 Evoqua Water Technologies Llc Method of irradiating a liquid
US8753522B2 (en) 2007-04-03 2014-06-17 Evoqua Water Technologies Llc System for controlling introduction of a reducing agent to a liquid stream
US8741155B2 (en) 2007-04-03 2014-06-03 Evoqua Water Technologies Llc Method and system for providing ultrapure water
US9725343B2 (en) 2007-04-03 2017-08-08 Evoqua Water Technologies Llc System and method for measuring and treating a liquid stream
US20080245737A1 (en) * 2007-04-03 2008-10-09 Siemens Water Technologies Corp. Method and system for providing ultrapure water
US8961798B2 (en) 2007-04-03 2015-02-24 Evoqua Water Technologies Llc Method for measuring a concentration of a compound in a liquid stream
US9365435B2 (en) 2007-04-03 2016-06-14 Evoqua Water Technologies Llc Actinic radiation reactor
CA2683415A1 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited An oral pharmaceutical composition
PT2157967E (en) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2685118C (en) 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
AR066146A1 (en) 2007-04-27 2009-07-29 Shionogi & Co Trpvi antagonists and uses thereof
EP2091936B1 (en) 2007-04-27 2013-05-15 Purdue Pharma LP Therapeutic agents useful for treating pain
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
CA2687130C (en) * 2007-05-07 2017-10-03 Evonik Roehm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US8007707B1 (en) 2007-05-15 2011-08-30 Fresh Products, Inc. Method of manufacture air freshening article
CN101686672A (en) 2007-05-31 2010-03-31 塞普拉柯公司 Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2581081A3 (en) 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2009011988A2 (en) * 2007-06-05 2009-01-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090042987A1 (en) * 2007-07-06 2009-02-12 Michael Lionel Selley Treatment of neuropathic pain
BRPI0814542A2 (en) * 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Methods and compositions for the treatment of cancer, tumors and tumor-related disorders
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
EP2019101A1 (en) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
US8435996B2 (en) 2007-08-01 2013-05-07 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
WO2009017831A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CA2695583A1 (en) 2007-08-13 2009-02-19 Metabasis Therapeutics, Inc. Novel activators of glucokinase
JP5965583B2 (en) * 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー Abuse-resistant pharmaceutical composition, its use and a manufacturing method
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
ES2534546T3 (en) 2007-08-31 2015-04-24 Purdue Pharma Lp Piperidine compounds, quinoxaline substituted type and uses thereof
BRPI0816798A2 (en) * 2007-09-11 2016-10-11 Activx Biosciences Inc compound, pharmaceutical composition, methods for inhibiting glycogen synthase kinase action-3, and for treating, preventing or ameliorating a disease, the use of a compound, and article of manufacture
EP2203459B1 (en) 2007-09-12 2016-03-16 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as gsk-3 inhibitors
AU2008305581C1 (en) 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
KR100946553B1 (en) * 2007-10-11 2010-03-11 주식회사 엘지생활건강 A film typed cleaning agent
JP5629581B2 (en) 2007-10-12 2014-11-19 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド Method of treating gastrointestinal disorders that is independent of the intake of food
MX2010003757A (en) * 2007-10-16 2010-04-27 Symphogen As Compositions comprising optimized her1 and her3 multimers and methods of use thereof.
CA2702710C (en) 2007-10-16 2013-05-07 Repros Therapeutics, Inc. Trans-clomiphene for metabolic syndrome
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
WO2009052454A2 (en) 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009079375A1 (en) 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2710515A1 (en) * 2007-12-28 2009-07-09 Khashayar Kevin Neshat Controlled release local anesthetic for post dental surgery and method of use
EP2240443B1 (en) * 2008-01-08 2013-11-20 Purdue Pharma LP Proline analogs as ligands for cannabinoid receptors for the treatment of pain
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090232796A1 (en) * 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
TWI395593B (en) 2008-03-06 2013-05-11 Halozyme Inc In vivo temporal control of activatable matrix-degrading enzymes
ES2610989T3 (en) 2008-03-17 2017-05-04 Ambit Biosciences Corporation 1- (3- (6,7-dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropane-2-ol) isoxazol-3-yl) urea as a modulator RAF kinases in the treatment of cancer diseases
MX2010010272A (en) 2008-03-19 2011-05-25 Chembridge Corp Novel tyrosine kinase inhibitors.
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
KR20140142323A (en) 2008-03-27 2014-12-11 셀진 코포레이션 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP3192525A1 (en) 2008-04-14 2017-07-19 Halozyme, Inc. Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
DE102008021473A1 (en) * 2008-04-29 2009-11-12 Heraeus Kulzer Gmbh equipped with anti-plaque agent (s) dental materials
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
EP2303327A2 (en) * 2008-05-20 2011-04-06 Cerenis Therapeutics S.A. Niacin and nsaid for combination therapy
EP2476690A1 (en) 2008-07-02 2012-07-18 IDENIX Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
IT1393244B1 (en) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano System for the release to the colon of drugs susceptible to enzymatic degradation and / or poorly absorbed in the gastrointestinal tract
JP5416210B2 (en) * 2008-07-21 2014-02-12 パーデュー、ファーマ、リミテッド、パートナーシップ Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and their uses
ME01665B (en) 2008-07-30 2014-09-20 Purdue Pharma Lp Buprenorphine analogs
CN102292316B (en) 2008-08-13 2015-07-01 症变治疗公司 Glucagon antagonists
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Boron-containing small molecules
WO2010039237A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
TWI480272B (en) 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
JP2012505241A (en) * 2008-10-10 2012-03-01 パーデュー・リサーチ・ファウンデーションPurdue Research Foundation The therapeutic compositions of Alzheimer's disease
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
KR101696938B1 (en) 2008-10-29 2017-01-16 셀진 코포레이션 Isoindoline-compound for use in the treatment of cancer
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2376083A4 (en) * 2008-11-20 2012-06-20 Purdue Research Foundation Quinazoline inhibitors of bace 1 and methods of using
WO2010065861A2 (en) 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
MX2011006110A (en) 2008-12-09 2011-06-24 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof.
JP5749176B2 (en) 2008-12-16 2015-07-15 スノビオン プハルマセウトイカルス インコーポレイテッド Triple reuptake inhibitors and methods for their use
US20110306605A1 (en) 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer
AU2009330192A1 (en) 2008-12-22 2011-07-14 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
AU2009332963B2 (en) 2008-12-31 2015-02-05 Upsher-Smith Laboratories, Llc Opioid-containing oral pharmaceutical compositions and methods
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
ES2668909T3 (en) 2009-01-06 2018-05-23 Galenagen, Llc Compositions comprising protease, amylase and lipase for use in the treatment of Staphylococcus aureus infections
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
DE102009004368A1 (en) 2009-01-08 2010-07-15 Heraeus Kulzer Gmbh Dental materials containing antimicrobial agents for the prevention of plaque deposits
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
CN102340992B (en) 2009-02-09 2014-11-05 桑诺维恩药品公司 Pyrrolidine triple reuptake inhibitors
EP2818164A1 (en) 2009-02-10 2014-12-31 Celgene Corporation Methods of using and compositions comprising PDE4-modulators for treatment, prevention and management of tuberculosis
BRPI1008020A2 (en) 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc H3 antagonists and inverse agonists of the histamine and methods of use thereof
AU2010292287A1 (en) 2009-09-11 2012-03-15 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
KR20110124780A (en) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 Prebiotic formulations and methods of use
EP2448406B1 (en) * 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
PT2401267E (en) 2009-02-27 2014-04-10 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and their use in methods
JP5690286B2 (en) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス,インコーポレイテッド Phosphonate thiophene and Hosuhochiazoru hcv polymerase inhibitors
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010105016A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
WO2010104205A1 (en) * 2009-03-11 2010-09-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
US8811578B2 (en) * 2009-03-23 2014-08-19 Telemanager Technologies, Inc. System and method for providing local interactive voice response services
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8772184B2 (en) 2009-03-31 2014-07-08 Illinois Tool Works Inc. Reversible color-changing sanitizer-indicating nonwoven wipe
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP2421524B1 (en) 2009-04-20 2018-08-08 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP2421830B1 (en) 2009-04-22 2014-04-02 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide ccr3 antagonists
WO2010123960A2 (en) 2009-04-22 2010-10-28 Axikin Pharmaceuticals, Inc. Arylsulfonamide ccr3 antagonists
AR078120A1 (en) 2009-04-22 2011-10-19 Axikin Pharmaceuticals Inc CCR3 antagonists arylsulfonamide 2,5-disubstituted and pharmaceutical compositions
EP2429992A4 (en) * 2009-05-15 2012-11-28 Univ Kentucky Res Found Treatment of mci and alzheimer's disease
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
EP3300723A1 (en) 2009-05-18 2018-04-04 Sigmoid Pharma Limited Composition comprising oil drops
JP5645816B2 (en) 2009-05-25 2014-12-24 国立大学法人東京工業大学 A pharmaceutical composition comprising a core factor of the growth and differentiation of central neurons
US20120077802A1 (en) 2009-06-10 2012-03-29 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US8741267B1 (en) * 2009-06-26 2014-06-03 Joseph P. Trovato Method for treating periodontal disease
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
DK3072890T3 (en) 2009-07-07 2019-02-11 Mei Pharma Inc Pyrimidinyl and 1,3,5-triazinylbenzimidazoler and their use in cancer therapy
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
DK2451435T3 (en) 2009-07-08 2018-01-15 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8591730B2 (en) 2009-07-30 2013-11-26 Siemens Pte. Ltd. Baffle plates for an ultraviolet reactor
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
BR112012002963A2 (en) 2009-08-12 2017-10-24 Sigmoid Pharma Ltd immunomodulatory compositions comprising a polymer matrix and an oily phase
KR20120059558A (en) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 Biaryl compounds and methods of use thereof
KR20120081120A (en) 2009-09-04 2012-07-18 유나이티드 파라곤 어소시에이츠 인크. Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
CA2773521C (en) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
RU2547990C2 (en) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Fast achievement and/or completion of substantial stable drug delivery
US20110136751A1 (en) 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
NZ599445A (en) 2009-10-19 2014-04-30 Synta Pharmaceuticals Corp Combination cancer therapy with hsp90 inhibitory compounds
WO2011056566A2 (en) 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
US20140004182A1 (en) 2009-11-19 2014-01-02 Jerome B. Zeldis Methods for the treatment of sarcoidosis
HUE037281T2 (en) * 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181466A1 (en) 2009-12-04 2012-07-30 Sunovion Pharmaceuticals Inc Formulations, salts and polymorphs of transnorsertraline and uses thereof
KR20180049235A (en) 2009-12-04 2018-05-10 선오비온 파마슈티컬스 인코포레이티드 Multicyclic compounds and methods of use thereof
EP2509615A1 (en) 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
CN102822175A (en) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
AU2010333767A1 (en) 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
AU2010339460A1 (en) 2009-12-30 2012-07-19 Scynexis Inc. Cyclosporine analogues
CN107661490A (en) 2010-01-04 2018-02-06 Mapi医药公司 Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MX337566B (en) 2010-01-05 2016-03-10 Celgene Corp A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer.
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EA027622B1 (en) 2010-02-05 2017-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Solid state forms of macrocyclic kinase inhibitors
US8518972B2 (en) 2010-02-11 2013-08-27 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP2542542B1 (en) 2010-03-02 2015-04-22 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
WO2011112933A1 (en) 2010-03-12 2011-09-15 Celgene Corporation Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
TW201134820A (en) 2010-03-17 2011-10-16 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
JP2013522321A (en) 2010-03-19 2013-06-13 パーデュー・リサーチ・ファウンデーションPurdue Research Foundation ccr5 modulators for the treatment of Hiv
CA2794096A1 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
EP2556082B1 (en) 2010-04-08 2017-02-22 Emory University Substituted androst-4-ene diones
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2011133521A2 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
JP2013526523A (en) 2010-05-11 2013-06-24 シマ ラブス インク. Alcohol resistant sustained release oral dosage form comprising metoprolol
WO2012037072A1 (en) 2010-09-13 2012-03-22 Synta Pharmaceuticals Corporation Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
AU2011255438A1 (en) 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
WO2011149824A1 (en) 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
NZ705135A (en) 2010-05-26 2017-10-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
JP2013528180A (en) 2010-05-28 2013-07-08 ジーイー・ヘルスケア・リミテッド Radiolabeled compounds and a method of manufacturing the same
JP6019015B2 (en) 2010-06-01 2016-11-02 ビオトヘルイク, インコーポレイテッド 6-cyclohexyl-1-hydroxy-4-methyl -2 (1h) - a method of treatment of hematologic malignancies that uses pyridone
AU2011261499B2 (en) 2010-06-01 2015-07-16 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
CN103108868B (en) 2010-06-07 2015-11-25 诺沃梅迪科斯有限公司 Furanyl compounds and their use
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
EP2590636A1 (en) 2010-07-06 2013-05-15 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
CN101987083B (en) * 2010-07-16 2012-12-12 钟术光 Preparation method for controlled release preparation, especial for zero-order release controlled release preparation
EP2595615A1 (en) 2010-07-19 2013-05-29 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012025217A1 (en) 2010-08-24 2012-03-01 Algiax Pharmaceuticals Gmbh Novel use of leflunomide and malononitrilamides
US20130225614A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
MX2013002383A (en) 2010-09-01 2013-07-05 Ambit Biosciences Corp Hydrobromide salts of a pyrazolylaminoquinazoline.
CN103298805A (en) 2010-09-01 2013-09-11 埃姆比特生物科学公司 Quinazoline compounds and methods of use thereof
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030894A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
JP5932794B2 (en) 2010-09-01 2016-06-08 アムビト ビオスシエンセス コルポラチオン Pyrazolyl quinazoline and pharmaceutical compositions thereof and methods of using an optically active
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
US8772185B2 (en) 2010-10-15 2014-07-08 Illinois Tool Works Inc. Reversible color-changing ink formulations and nonwoven wipes
EP2627349B1 (en) 2010-10-15 2016-02-03 The Trustees of Columbia University in the City of New York Obesity-related genes and their proteins and uses thereof
RU2576402C2 (en) 2010-10-18 2016-03-10 Серенис Терапьютикс Холдинг Са Compounds, compositions and methods suitable for cholesterol mobilisation
BR112013009635A2 (en) 2010-10-19 2016-07-12 Elcelyx Therapeutics Inc binder based therapies chemosensory receptor
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
HUE034890T2 (en) 2010-10-29 2018-03-28 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
US20130289071A1 (en) 2010-11-09 2013-10-31 Synta Pharmaceuticals Corp. Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc Methods for treating baldness and promoting hair growth
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2012078757A2 (en) 2010-12-08 2012-06-14 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
CA2821805A1 (en) 2010-12-16 2012-06-21 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
UA114887C2 (en) 2010-12-22 2017-08-28 Пюрдю Фарма Л.П. Encased tamper resistant controlled release dosage forms
EP2654751B1 (en) 2010-12-22 2016-11-23 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
NZ612996A (en) 2010-12-23 2015-05-29 Purdue Pharma Lp Tamper resistant solid oral dosage forms
AU2012363873B2 (en) 2012-01-06 2017-11-23 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
ES2673114T3 (en) 2011-01-10 2018-06-19 Celgene Corporation Fenetilsulfona isoindoline derivatives as PDE 4 and / or cytokines
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
MX2013007959A (en) 2011-01-10 2013-12-06 Celgene Corp Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl] -3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide.
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
EP2663305A1 (en) 2011-01-11 2013-11-20 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
CN103338753A (en) 2011-01-31 2013-10-02 细胞基因公司 Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103502224A (en) 2011-02-23 2014-01-08 克鲁莱斯有限公司 Flumazenil complexes, compositions comprising same and uses thereof
EP2678013A1 (en) 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
CA2827739A1 (en) 2011-02-24 2012-10-18 Synta Pharmaceuticals Corp. Prostate cancer therapy with hsp90 inhibitory compounds
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
EP3320902A1 (en) 2011-03-07 2018-05-16 Celgene Corporation Methods for treating diseases using isoindoline compounds
US20120232159A1 (en) 2011-03-07 2012-09-13 Tonix Pharmaceuticals, Inc. Methods and Compositions for Treating Depression using Cyclobenzaprine
US8906932B2 (en) 2011-03-11 2014-12-09 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4Hquinazolin-3-yl)-piperidine-2,6-dione
RS56770B1 (en) 2011-03-11 2018-04-30 Celgene Corp Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2012123406A1 (en) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of imidazotriazinones
US20140057978A1 (en) 2011-03-17 2014-02-27 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CA2867134A1 (en) 2011-03-28 2012-10-04 Sheila Dewitt 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20140088102A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
RU2608742C2 (en) 2011-03-28 2017-01-23 ЭмИАй ФАРМА, ИНК. (alpha-substituted aralkylamino- and heteroarylalkylamino)pyrimidinyl- and 1,3,5-triazinylbenzimidazoles, pharmaceutical compositions thereof and use thereof in treating proliferative diseases
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US20120321590A1 (en) 2011-04-06 2012-12-20 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds
JP2014510140A (en) 2011-04-07 2014-04-24 ザ プロクター アンド ギャンブル カンパニー Conditioner compositions adhesion of polyacrylate microcapsules increased
CN103458858B (en) 2011-04-07 2016-04-27 宝洁公司 Deposited with enhanced polyacrylate microcapsules shampoo composition
JP6283607B2 (en) 2011-04-07 2018-02-21 ザ プロクター アンド ギャンブル カンパニー Personal cleansing composition polyacrylate microcapsules deposited is increased
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
CA2834355A1 (en) 2011-04-28 2012-11-01 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
NZ617142A (en) 2011-04-29 2015-11-27 Celgene Corp Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
JP5985611B2 (en) 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション Compounds for inflammatory and immune-related applications
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
WO2012162372A1 (en) 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2527301B1 (en) 2011-05-26 2016-04-27 Evoqua Water Technologies GmbH Method and arrangement for a water treatment
JP2014522396A (en) 2011-05-27 2014-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションTemple University−Of The Commonwealth System Of Higher Education Substituted 2-benzylidene -2H- benzo [b] [1,4] thiazine -3 (4H) - one, the use of the derivatives and their therapeutic
AU2012268119B2 (en) 2011-06-07 2017-03-02 Anadys Pharmaceuticals, Inc. [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
RU2011122942A (en) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" New kinase inhibitors
CN103717594B (en) 2011-06-22 2016-12-14 普渡制药公司 Dihydroxy-substituted group containing an antagonist and the use thereof trpv1
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
KR20140042868A (en) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 Novel fluoroergoline analogs
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
AU2012280931A1 (en) 2011-07-07 2014-02-27 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds
US20130011444A1 (en) 2011-07-09 2013-01-10 Syntrix Biosystems, Inc. Compositions and methods for overcoming resistance to tramadol
JP6027610B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds and their use
MX2014000648A (en) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
EP3351527A1 (en) 2011-08-04 2018-07-25 Repros Therapeutics Inc. Trans-clomiphene metabolites and uses thereof
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
CN103930126A (en) 2011-08-12 2014-07-16 Bsrc亚历山大.弗莱明 TNF superfamily trimerization inhibitors
AU2012299177A1 (en) 2011-08-19 2014-04-10 Synta Pharmaceuticals Corp. Combination cancer therapy of HSP90 inhibitor with antimetabolite
EP2959899B1 (en) 2011-08-23 2017-02-22 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
AR088441A1 (en) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Carboniloximetilfosforamidato substituted compounds and pharmaceutical compositions for treating viral infections
US8951985B2 (en) 2011-09-12 2015-02-10 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
US9243394B2 (en) 2011-09-20 2016-01-26 Fresh Products, Inc. Replaceable restroom urinal assemblies, including urinal screens
JP2014526558A (en) 2011-09-23 2014-10-06 セルジーン コーポレイション Romidepsin and 5-azacytidine for use in the treatment of lymphoma
EP2760456A1 (en) 2011-09-26 2014-08-06 Celgene Corporation Combination therapy for chemoresistant cancers
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013051001A1 (en) 2011-10-06 2013-04-11 Yeda Research And Development Co. Ltd. Combination therapy with erbb ligands binding molecules
US9610370B2 (en) 2011-10-07 2017-04-04 University Of Virginia Patent Foundation Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
WO2013055985A1 (en) 2011-10-12 2013-04-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
TW201811777A (en) 2011-10-14 2018-04-01 Ambit Biosciences Corp Heterocyclic compounds and methods of use thereof
AR089650A1 (en) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc 3,5-cyclic phosphate compounds substituted purine nucleotide and pharmaceutical compositions for treating viral infections
WO2013067043A1 (en) 2011-11-01 2013-05-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
JP2014533299A (en) 2011-11-14 2014-12-11 シンタ ファーマシューティカルズ コーポレーション The combination therapy of Braf inhibitors and hsp90 inhibitors
JP2014533744A (en) 2011-12-01 2014-12-15 パーデュー、ファーマ、リミテッド、パートナーシップ Azetidine Substituted-Quinoxaline-Type Piperidine Compounds and their uses
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
US9096606B2 (en) 2011-12-08 2015-08-04 Purdue Pharma, L.P. Quarternized buprenorphine analogs
SG11201403434YA (en) 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
EP2793583A4 (en) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc Novel neuromodulatory compounds
ES2609582T3 (en) 2011-12-30 2017-04-21 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
SG11201403746SA (en) 2012-01-05 2014-07-30 Boston Medical Ct Corp Slit-robo signaling for diagnosis and treatment of kidney disease
US10189825B2 (en) 2012-02-08 2019-01-29 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013126394A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
NZ628084A (en) 2012-03-16 2016-09-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
JP6124986B2 (en) 2012-03-19 2017-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Growth differentiation factor for treating diastolic heart failure (gdf)
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US9169207B2 (en) 2012-03-27 2015-10-27 Incuron, Llc Curaxins for use in treating carcinogen-induced cancer
US20150051203A1 (en) 2012-03-28 2015-02-19 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
PL2833905T3 (en) 2012-04-04 2019-01-31 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
JP2015515477A (en) 2012-04-04 2015-05-28 シンタ ファーマシューティカルズ コーポレーション Novel triazole compounds that modulate Hsp90 activity
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
US8946253B2 (en) 2012-04-17 2015-02-03 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2911041A1 (en) 2012-05-01 2013-11-07 Shelley Romayne BOYD Methods for treating and diagnosing blinding eye diseases
AU2013259267A1 (en) 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
GB201208315D0 (en) 2012-05-11 2012-06-27 Numedicus Ltd Pharmaceutical methods and compositions
EP2858976B1 (en) 2012-05-11 2018-03-14 Purdue Pharma LP Benzomorphan compounds as opioid receptors modulators
EP2852603A1 (en) 2012-05-22 2015-04-01 IDENIX Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP3406598A1 (en) 2012-06-14 2018-11-28 Mayo Foundation for Medical Education and Research Pyrazole derivatives as inhibitors of stat3
CN104582732A (en) 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 Compositions for treating cancer and methods for making the same
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
ES2699810T3 (en) 2012-06-29 2019-02-12 Celgene Corp Methods to determine the efficacy of drugs using cereblon-associated proteins
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US9034870B2 (en) 2012-07-13 2015-05-19 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
TW201434466A (en) 2012-08-09 2014-09-16 Celgene Corp Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014030053A1 (en) 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
EP2890370A4 (en) 2012-08-31 2016-09-28 Univ California Agents useful for treating obesity, diabetes and related disorders
EP2892884A1 (en) 2012-09-07 2015-07-15 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
SG11201501653RA (en) 2012-09-10 2015-04-29 Celgene Corp Methods for the treatment of locally advanced breast cancer
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
ES2674980T3 (en) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Nucleoside 2'-chloro for HCV infection
CA2887528A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
EP2909222A1 (en) 2012-10-22 2015-08-26 IDENIX Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
CN105102000A (en) 2012-11-01 2015-11-25 无限药品公司 Treatment of cancers using PI3 kinase isoform modulators
MX2015005160A (en) 2012-11-02 2015-07-17 Repros Therapeutics Inc Trans-clomiphene for use in cancer therapy.
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
EP2917182B1 (en) 2012-11-09 2018-01-03 Purdue Pharma LP Benzomorphan analogs and the use thereof
US20150290171A1 (en) 2012-11-09 2015-10-15 Celgene Corporation Methods for the treatment of bone loss
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
EP3255050A1 (en) 2012-11-29 2017-12-13 Sunovion Pharmaceuticals Inc. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
MX2015006544A (en) 2012-11-30 2015-09-24 Novomedix Llc Substituted biaryl sulfonamides and the use thereof.
EP2931729B1 (en) 2012-12-07 2019-02-06 Purdue Pharma LP Buprenorphine analogs as opiod receptor modulators
JP6163210B2 (en) 2012-12-14 2017-07-12 パーデュー、ファーマ、リミテッド、パートナーシップ Nitrogen-containing morphinan derivatives and their use
US8987287B2 (en) 2012-12-14 2015-03-24 Purdue Pharma L.P. Spirocyclic morphinans and their use
CA2894963A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
SG11201504931SA (en) 2012-12-21 2015-07-30 Map Pharmaceuticals Inc Novel methysergide derivatives
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
EP2941430B1 (en) 2012-12-28 2017-04-26 Purdue Pharma LP 7,8-cyclicmorphinan analogs
JP6159417B2 (en) 2012-12-28 2017-07-05 パーデュー、ファーマ、リミテッド、パートナーシップ Substituted morphinan and its use
EP2938341B1 (en) 2012-12-31 2018-09-05 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
JP6333855B2 (en) 2013-01-05 2018-05-30 エルセリクス セラピューティクス インコーポレイテッド Delayed release composition comprising a biguanide
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
EP2943188A1 (en) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamins c and k for treating polycystic diseases
CA2935495A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
JP6406713B2 (en) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス, インコーポレイテッド Treatment of depression and other diseases with low dose drug
WO2014118618A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
JP6208261B2 (en) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップPurdue Pharma L.P. Tampering resistant pharmaceutical preparations
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
CN105050624A (en) 2013-03-14 2015-11-11 细胞基因公司 Treatment of psoriatic arthritis using apremilast
ES2687958T3 (en) 2013-03-15 2018-10-30 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105120659A (en) 2013-03-15 2015-12-02 度瑞公司 Compositions with a rheological modifier to reduce dissolution variability
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9636408B2 (en) 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
EP2981542A1 (en) 2013-04-01 2016-02-10 IDENIX Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
SG11201507759WA (en) 2013-04-02 2015-10-29 Celgene Corp Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
DE102013009114A1 (en) 2013-05-29 2014-12-04 Franz Gerstheimer A pharmaceutical composition for overcoming Metabolisierungsproblemen
EP3004130A1 (en) 2013-06-05 2016-04-13 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
EP3004396A4 (en) 2013-06-06 2017-03-01 The General Hospital Corporation Methods and compositions for the treatment of cancer
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
ES2703623T3 (en) 2013-06-28 2019-03-11 Purdue Pharma Lp Opioid antagonists for use in the treatment of arrhythmia induced by opioid analgesics
TW201534726A (en) 2013-07-03 2015-09-16 Halozyme Inc Thermally stable PH20 hyaluronidase variants and uses thereof
JP2016525138A (en) 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. The combination of oxycodone and naloxone for use in the treatment of pain in patients suffering from diseases increase the risk for diseases and / or Enterobacteriaceae migration results in pain and intestinal Disconnect bio cis
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CA2924141A1 (en) 2013-08-22 2015-02-26 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
WO2015031613A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3049082A1 (en) 2013-09-24 2016-08-03 Purdue Pharma LP Treatment of burn pain by trpv1 modulators
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
SG11201602445SA (en) 2013-10-04 2016-04-28 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065876A1 (en) 2013-10-29 2015-05-07 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9988392B2 (en) 2013-12-26 2018-06-05 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3087079B1 (en) 2013-12-26 2019-04-03 Purdue Pharma LP Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015102682A1 (en) 2013-12-30 2015-07-09 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
CN106132487A (en) * 2014-01-23 2016-11-16 毛利人南卡罗来纳州有限公司 Scented body compositions
WO2015112568A1 (en) 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN106458878B (en) 2014-03-18 2018-08-31 艾格埃克斯制药有限公司 2-cyano-3-cyclopropyl-3-hydroxy -n- aryl - thioacrylamide derivative
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JP2017508816A (en) 2014-03-20 2017-03-30 カペラ セラピューティクス,インコーポレーテッド Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
JP2017515854A (en) 2014-05-12 2017-06-15 クオナトウス ファーマシューティカルズ,インコーポレイテッド Treatment of complications of chronic liver disease by caspase inhibitors
US9480676B2 (en) 2014-05-15 2016-11-01 Celgene Corporation Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2015176780A1 (en) 2014-05-23 2015-11-26 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
KR20170005492A (en) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 Nucleoside derivatives for the treatment of cancer
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US20170143671A1 (en) 2014-06-23 2017-05-25 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
JP2017528690A (en) 2014-06-27 2017-09-28 セルジーン コーポレイション Compositions and methods for inducing a conformational change in cereblon and other e3 ubiquitin ligase
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3188745A1 (en) 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
EA201790439A1 (en) 2014-08-22 2017-07-31 Селджин Корпорейшн Methods for treating multiple myeloma using the immunomodulatory compounds in combination with antibodies
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EA201790628A1 (en) 2014-09-15 2017-06-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния nucleotide analogs
BR112017005574A2 (en) 2014-09-19 2017-12-12 Procter & Gamble Pulsed-release dosage forms of phenylephrine
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20170065032A (en) 2014-10-14 2017-06-12 할로자임, 아이엔씨 Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof and Methods of Using Same
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
TN2017000157A1 (en) 2014-10-21 2018-10-19 Ariad Pharma Inc Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
DE202015102279U1 (en) 2014-11-05 2015-08-14 Fresh Products, Inc. urinal
USD778411S1 (en) 2014-11-05 2017-02-07 Fresh Products, Inc. Urinal screen
USD778412S1 (en) 2014-11-10 2017-02-07 Fresh Products, Inc. Urinal screen
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
AR103264A1 (en) 2014-12-23 2017-04-26 Axikin Pharmaceuticals Inc 3,5-aminopyrazole derivatives as kinase inhibitors rc
CA2974113A1 (en) 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
MX2017009405A (en) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Ergoline compounds and uses thereof.
JP2018504446A (en) 2015-02-09 2018-02-15 シンタ ファーマシューティカルズ コーポレーション Combination therapy hsp90 inhibitors and pd-1 inhibitors for the treatment of cancer
MX2017011606A (en) 2015-03-10 2017-10-26 Rhodes Tech Acetate salt of buprenorphine and methods for preparing buprenorphine.
TW201642857A (en) 2015-04-06 2016-12-16 Celgene Corp Treatment of hepatocellular carcinoma using combination therapy
CN108368147A (en) 2015-05-27 2018-08-03 南方研究院 Nucleotides for treatment of cancer
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
JP2018527302A (en) 2015-06-26 2018-09-20 セルジーン コーポレイション The method of treating Kaposi's sarcoma or kshv induced lymphomas with an immunomodulatory compound, and the use of biomarkers
KR20180037228A (en) 2015-07-28 2018-04-11 바이옴 바이오사이언스 피브이티. 엘티디. Anti-bacterial drugs and preventive agents
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017064657A1 (en) 2015-10-16 2017-04-20 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
MX2018005136A (en) 2015-10-30 2018-05-07 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof.
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP3371311A1 (en) 2015-11-06 2018-09-12 Orionis Biosciences NV Bi-functional chimeric proteins and uses thereof
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
BR112018013558A2 (en) 2015-12-31 2018-12-04 Conatus Pharmaceuticals Inc method of treatment of a liver disease in an individual, method of use of a caspase inhibitor, a method to reduce or sustain a meld classification or its components, method of treating, reducing or sustain a meld classification or its components, method of treating, reduce or sustain a Child-Pugh score or components thereof, pharmaceutical composition comprising a caspase inhibitor, kit, method of treatment of liver cirrhosis method of treatment and prevention of high meld classification method of treatment of liver cirrhosis and prevention a high Child-Pugh classification
SG11201805779TA (en) 2016-01-08 2018-08-30 Celgene Corp Antiproliferative compounds, and their pharmaceutical compositions and uses
AU2017206039A1 (en) 2016-01-08 2018-07-19 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3411407A1 (en) 2016-02-05 2018-12-12 Orionis Biosciences NV Bispecific signaling agents and uses thereof
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
CA3016849A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
AU2017258781A1 (en) 2016-04-29 2018-11-22 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
EP3452473A1 (en) 2016-05-04 2019-03-13 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
WO2017194782A2 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
TW201805271A (en) 2016-05-16 2018-02-16 Biotheryx Inc Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CA3030805A1 (en) 2016-07-18 2018-01-25 Pharmena S.A. 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein
TW201817423A (en) 2016-07-26 2018-05-16 Purdue Pharma Lp Treatment and prevention of sleep disorders
AU2017301769A1 (en) 2016-07-29 2019-02-14 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
WO2018049080A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018069312A1 (en) 2016-10-11 2018-04-19 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
US20180243285A1 (en) 2017-01-27 2018-08-30 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
WO2018145089A1 (en) 2017-02-06 2018-08-09 Spero Therapeutics, Inc. Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3432883A1 (en) 2017-02-21 2019-01-30 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018165142A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2018183781A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183782A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018213807A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
WO2018213810A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
WO2019018247A1 (en) 2017-07-16 2019-01-24 Neuere, Llc Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US3901969A (en) * 1973-09-10 1975-08-26 Union Corp Sustained release of methantheline
US3901968A (en) * 1973-09-10 1975-08-26 Union Corp Sustained release of methantheline
JPS5312569B2 (en) * 1974-06-11 1978-05-02
US4088798A (en) * 1975-11-11 1978-05-09 Sandoz, Inc. Methods for the preparation of controlled gastric residence time medicament formulations
US4026932A (en) * 1975-12-11 1977-05-31 The Dow Chemical Company Method for converting alkenoic acid copolymer latexes into water solutions
JPS5911563B2 (en) * 1980-02-27 1984-03-16 Japan Atomic Energy Res Inst
JPS6111933B2 (en) * 1981-01-19 1986-04-05 Tanabe Seiyaku Co
DE3208791A1 (en) * 1982-03-11 1983-09-22 Roehm Gmbh A process for coating drug forms Mittes a dispersed in water ueberzugsmittels
US4553973A (en) * 1982-07-12 1985-11-19 Alza Corporation Process for preparing osmotic device
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5219621A (en) * 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
JPS60166608A (en) * 1984-02-08 1985-08-29 Japan Atom Energy Res Inst Slow-releasing composite having sandwich structure and its preparation
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
EP0164669B1 (en) * 1984-06-13 1991-01-23 Röhm Gmbh Process for coating pharmaceutical forms
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
CH666405A5 (en) * 1985-06-24 1988-07-29 Ciba Geigy Ag Strong, durable dosage forms with elastic filmueberzug.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
IT1214629B (en) * 1985-08-29 1990-01-18 Formenti Farmaceutici Spa Process of microencapsulation of a medicament, medicament cosi'preparato, and pharmaceutical compositions which comprise
US4837004A (en) * 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
IT1204294B (en) * 1986-03-11 1989-03-01 Gentili Ist Spa Method of manufacture of granular acts to production of coated tablets, for oral use, controlled release
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JP2668880B2 (en) * 1987-06-23 1997-10-27 日本油脂株式会社 Manufacturing method for coating amino acids
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
FR2624732B1 (en) * 1987-12-21 1991-02-15 Synthelabo A pharmaceutical sustained release formulation
EP0327295A3 (en) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracycline dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
IT1230576B (en) * 1988-10-20 1991-10-28 Angeli Inst Spa Pharmaceutical compositions for oral selective release in the colon
US5085866A (en) * 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
FR2643572A1 (en) * 1988-12-22 1990-08-31 Rhone Poulenc Chimie A method for encapsulating particles by coating by means of a thermoplastic silicone copolymer
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2036907C (en) * 1990-02-28 1996-10-22 Yuzo Miura 3-(substituted phenyl) pyrazole derivatives, a process for producing the same, herbicidal composition containing the same and method of controlling weeds using said composition
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
DE69111287T2 (en) * 1990-04-18 1995-12-21 Asahi Chemical Ind Spherical seed cores, spherical granules as well as processes for their preparation.
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
JP2558396B2 (en) * 1990-06-28 1996-11-27 田辺製薬株式会社 Controlled release formulation
JPH04230625A (en) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd Production of finely dispersed tablet composition comprising microcapsule containing spray-dried diclofenac sodium and having enteric coating
ZA9203474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
JP3142919B2 (en) * 1991-11-06 2001-03-07 旭化成株式会社 Cellulose derivatives latex and their preparation
BR9206797A (en) * 1991-11-22 1995-10-31 Procter & Gamble Pharma Compositions with delayed release of risedronate
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5681581A (en) * 1992-08-04 1997-10-28 Dunn; James M. Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5560930A (en) * 1993-12-27 1996-10-01 Shin-Etsu Chemical Co., Ltd. Method for preparing aqueous emulsion for coating solid pharmaceutical preparations
JPH07223970A (en) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd Releasing formulation at niche in digestive tract

Also Published As

Publication number Publication date
EP0636366A2 (en) 1995-02-01
AU686168B2 (en) 1998-02-05
US5639476A (en) 1997-06-17
US6143353A (en) 2000-11-07
CA2128591C (en) 1999-03-23
EP0636366A3 (en) 1998-02-04
AU6868994A (en) 1995-02-09
US5580578A (en) 1996-12-03

Similar Documents

Publication Publication Date Title
US3577516A (en) Preparation of spray on bandage
US3576760A (en) Water soluble entrapping
AU616472B2 (en) Infection-resistant compositions, medical devices and surfaces and method for preparing and using same
TW421599B (en) Multiple unit pharmaceutical preparation
AU686168B2 (en) Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW325405B (en) Pharmaceutical composition as a vaginal passary or suppository comprising antimicrobial agent and micro encapsulated bacteria
TW577757B (en) Immediate release tablet cores of insoluble drugs having sustained-release coating
AU676146B2 (en) Contrast agents consisting of galactose particles and an amphiphilic carboxylic acid
TW397683B (en) Treatment of inflammatory bowel disease using oral dosage forms of <omega>-3 polyunsaturates acids
US5334388A (en) Antimicrobial drying substrate
JP3220944B2 (en) Alginate hair setting composition
TWI267385B (en) Controlled release bead, pharmaceutical formulation comprising the same and production thereof
WO1991015187A1 (en) Hair styling compositions
CA2011826A1 (en) Film-forming emulsion containing iodine and methods of use
JP2006188539A (en) Controlled-release formulation coated with aqueous dispersion of ethyl cellulose
MXPA04003742A (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient.
CA2206233A1 (en) Combination dosage form comprising cetirizine and pseudoephedrine
EP1101489A3 (en) Sustained release heterodisperse hydrogel systems for insoluble drugs
EP1736144A3 (en) Orally disintegrable tablets
MY132877A (en) Biodegradable thermoplastic composition with improved wettability
WO2002072034A3 (en) Chronotherapeutic dosage forms
JPH032114A (en) Sustained release pharmaceutical composition
WO1999015210B1 (en) Bioadhesive compositions and methods for topical administration of active agents
US3966902A (en) Polymer complex carriers for an active ingredient
CA2187355A1 (en) An adjunctive polymer system for use with medical device

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140721